First day at #ACC25, here are the results of 10 trials presented today. I counted 3 NEJM, 1 Lancet, and 1 JAMA.
WARRIOR: Intensive medical therapy did not reduce major CV events at five years in women with suspected INOCA.
STRIDE: Semaglutide improved walking distance, symptoms, and quality of life in PAD with diabetes.
API-CAT: Low-dose apixaban was noninferior to full-dose for preventing VTE recurrence in cancer patients.
RIVAWAR: Rivaroxaban was as effective and safe as warfarin for post-MI LV thrombus resolution at three months.
FARES-II: Four-factor PCC was superior to frozen plasma for bleeding control in cardiac surgery.
REVERSE-IT: Bentracimab reversed ticagrelor’s antiplatelet effects in urgent surgery or major bleeding.
HOST-BR: Three-month DAPT reduced adverse events without more bleeding vs. one-month in high-bleeding-risk patients post-stent.
SOUL: Oral semaglutide reduced MACE by 14% over four years with no safety concerns.
ADVANCE-HTN: Lorundrostat significantly lowered systolic BP at 12 weeks in uncontrolled hypertension.
DAPA-TAVI: Dapagliflozin reduced mortality and heart failure worsening post-TAVI vs. standard care.
#ACC24#JACC LBCT SimPub: In #EMPACT-MI, #cvMI complicated by LV dysfxn or congestion portended a worse prognosis. Regardless of LV dysfxn severity or presence/absence of congestion, empagliflozin ⬇️ both first & total HF hospitalizations but not mortality in EMPACT-MI trial https://t.co/IWUKTkTWdH
In 2023 I received a lot of support from @WomenAs1 as one of the Escalator Award winners and with the acceptance to Climb Heart Failure. It is Women’s History Month and I want to acknowledge all the work you do for us.
Thank you for believing in me in times I have doubted myself.
🚨Our paper is live today on @JACCJournals
Sex Differences in Association of Physical Activity With All-Cause & Cardiovascular Mortality
🫀Women derived greater gains in mortality risk reduction from equivalent doses of physical activity🆚men
@SmidtHeart
https://t.co/GDOpiLUL7n
Tomorrow is #worldheartday and this Heart doctor couldn’t be more thrilled 😁
Let’s make heart-healthy choices a part of our daily routine.Happy World Heart Day🫀#healthyhabits#heartday
Left first climb session super inspired .Such privilege to spend time with an outstanding group of women that are leading our field forward.Honored to be here#Climb2023#heart failure
To survive academic medicine as a female physician you need to be prepared to face some bumps,knocks and bruises.Thanks to WAO we can climb the ladder an develop our expertise together.This is how Women Rise 🙌.Thank you#Climb2023.#WIM#CardioTwitter
Today's been an exciting day as we've notified all accepted #CLIMB2023 applicants! We can't wait to get started next month. 🥳
Don't forget all #WomenInMedicine can view the sessions afterward in the Talent Directory. Sign up here: https://t.co/t4xpLSOW6M
#WIC#CardioTwitter
@JGrapsa@IndahSP_MD@JACCJournals@MinnowWalsh@fischman_david I participated in the second cohort of the program ,I can attest that is humbling to see how so many talented people work tireslesly to bring us great quality articles.
As a plus, I was fortunated enough to received one on one feedback from the amazing @JGrapsa🤩.
@WomenAs1 Unfortunately,women are often under recognized because we fail to claim our achievements
We feel uncomfortable doing so.
We need to learn to value more our contributions
Don’t forget to apply for#CLIMB2023 and grow your clinical skills!
This year’s topics
🫀Coronary
🫀Heart Failure
🫀Pulmonary Embolism
Do not procrastinate a better future and apply today https://t.co/euqmDZYCI9
#MedTwitter#CardioTwitter@WomenAs1#WIM
¡Ya estamos en vivo en un nuevo Webinar del Grupo MIL para hablar sobre cómo aprovechar las oportunidades existentes para las mujeres intervencionistas latinoamericanas.
Súmese en vivo a través de zoom.
https://t.co/zSnjqEIWTj
⭐ HOY ¡En el día internacional de la mujer, SOLACI celebra con un evento virtual educativo imperdible!
👩⚕️ MIL entrenan más MIL: ¡Cómo no boicotear tus oportunidades!
🗓 08/03 - 19.00h
▶ Evento abierto
Regístrese
https://t.co/zSnjqEIWTj